Circulating soluble receptor for advanced glycation end product (sRAGE) and left ventricular hypertrophy in patients with chronic kidney disease (CKD)
Circulating soluble receptor for advanced glycation end product (sRAGE) and left ventricular hypertrophy in patients with chronic kidney disease (CKD)
复制标题
DOI：
10.1016/j.numecd.2010.11.008
复制
发表时间：
2012-09-01
影响因子：
3.9
通讯作者：
Zoccali, C.
中科院分区：
文献类型：
--
作者：
Leonardis, D.;Basta, G.;Zoccali, C.
背景和目的：晚期糖基化终产物（可溶性糖基化终产物或可溶性糖基化终产物）的诱饵受体参与左心室肥大（LVH）和心肌病心肌损伤，在心力衰竭患者中的实验模型和观察性研究支持了可溶性糖基化终产物减缓心脏病进展并防止死亡的假设。由于慢性肾脏病（CKD）患者的血浆肌酐水平升高，我们研究了CKD患者血浆肌酐水平与左室肥厚的关系。方法和结果：我们纳入了142例平均估计肾小球滤过率（eGFR）为32 ml/min/1.73 m（2）的患者和49例年龄和性别匹配的健康对照者。发现sweep与左室重量指数（LVMI）和平均室壁厚度（MWT）之间存在显著的负相关关系，但在对照组中没有发现这种相关性。一项bootstrap回归验证研究证实了sweep与这些变量之间联系的估计值。在协方差分析中，CKD患者LVMI和MWT与severity的斜率显著大于对照组。在逻辑回归分析中，1个对数单位的增加与CKDpatients.Conclusions中LVH的几率降低82%相关：sHBG是CKD患者LVH的反向标志物。这种关联产生了一种假设，即在该人群中，LVH通路可能是LVH的一个因果风险因素，内源性诱饵受体sleep阻断该通路可以减轻同一人群中的LVH。(c)2010 Elsevier BV保留所有权利。
Background and Aim: A decoy receptor for advanced glycation end product (soluble RAGE or sRAGE) is involved in left ventricular hypertrophy (LVH), and cardiomyopathy myocardial damage in experimental models and observational studies in patients with heart failure support the hypothesis that sRAGE attenuates the progression of heart disease and prevents death. Since sRAGE accumulates in patients with chronic kidney disease (CKD) we studied the relationship between plasma sRAGE with LVH in CKD patients.Methods and results: We enrolled 142 patients with an average estimated glomerular filtration rate (eGFR) of 32 ml/min/1.73 m(2) and 49 healthy control individuals matched for age and gender.Plasma sRAGE was significantly higher in CKD patients than in healthy controls. Significant inverse relationships were found between sRAGE with left ventricular mass index (LVMI) and mean wall thickness (MWT) but no such associations were found in controls. A bootstrap resampling validation study confirmed the estimates of the link between sRAGE and these variables. On covariance analysis, the slopes of LVMI and MWT to sRAGE were significantly steeper in CKD patients than in the controls. On logistic regression analysis 1 log unit increase in sRAGE was associated with a 82% decrease in the odds for LVH in CKD patients.Conclusions: sRAGE is an inverse marker of LVH in CKD patients. This association generates the hypothesis that the RAGE pathway could be a causal risk factor for LVH in this population and that blockade of this pathway by the endogenous decoy receptor sRAGE could attenuate LVH in the same population. (c) 2010 Elsevier B.V. All rights reserved.